Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118


Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma.

Zhuang J, Da Y, Li H, Han B, Wan X, Zhu T, Chen M, Duan M, Xu Y, Zhao Y, Shen T, Wua Y, Zhou D.

Leuk Res. 2014 Feb;38(2):188-93. doi: 10.1016/j.leukres.2013.11.010. Epub 2013 Nov 19.


[Clinical and cytogenetic characteristics of myeloma patients with overall survival less than 24 months].

Zhuang J, Tang W, Li H, Chen M, Han B, Zhu T, Duan M, Li J, Zhang W, Xu Y, Wang S, Zhao Y, Zhou D.

Zhonghua Yi Xue Za Zhi. 2015 Mar 17;95(10):736-40. Chinese.


Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation.

Hwang IH, Chung JS, Shin HJ, Choi YJ, Song MK, Seol YM, Cho GJ, Choi BG, Choi MK, Choi BK, Ahn KH, Shin KH, Lee HS, Nam HS, Hwang JM.

Korean J Intern Med. 2011 Mar;26(1):76-81. doi: 10.3904/kjim.2011.26.1.76. Epub 2011 Mar 2.


[Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].

Deng SH, Xu Y, Mai YJ, Wang YF, Zhao YZ, Zou DH, Qiu LG.

Zhonghua Xue Ye Xue Za Zhi. 2008 Apr;29(4):217-21. Chinese.


Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

Ludwig H, Adam Z, Hajek R, Greil R, Tóthová E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N.

J Clin Oncol. 2010 Oct 20;28(30):4635-41. doi: 10.1200/JCO.2010.28.1238. Epub 2010 Sep 7.


Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.

Inamoto Y, Kurahashi S, Imahashi N, Fukushima N, Adachi T, Kinoshita T, Tsushita K, Miyamura K, Naoe T, Sugiura I.

Am J Hematol. 2009 May;84(5):283-6. doi: 10.1002/ajh.21390.


High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.

Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimpasi S, Parcharidou A, Kartasis Z, Zomas A, Symeonidis A, Viniou NA, Anagnostopoulos N, Economopoulos T, Zervas K, Dimopoulos MA; Greek Myeloma Study Group, Greece.

Eur J Haematol. 2010 Aug;85(2):114-9. doi: 10.1111/j.1600-0609.2010.01466.x. Epub 2010 May 6.


Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.

Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G.

Exp Hematol. 2003 Jan;31(1):73-80.


Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.

Moulopoulos LA, Dimopoulos MA, Kastritis E, Christoulas D, Gkotzamanidou M, Roussou M, Koureas A, Migkou M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Gika D, Koutoulidis V, Terpos E.

Am J Hematol. 2012 Sep;87(9):861-4. doi: 10.1002/ajh.23258. Epub 2012 May 28.


Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.

Rajkumar S, Fonseca R, Lacy M, Witzig T, Lust J, Greipp P, Therneau T, Kyle R, Litzow M, Gertz M.

Bone Marrow Transplant. 1999 Sep;24(5):497-503.


Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.

Landau H, Pandit-Taskar N, Hassoun H, Cohen A, Lesokhin A, Lendvai N, Drullinsky P, Schulman P, Jhanwar S, Hoover E, Bello C, Riedel E, Nimer SD, Comenzo RL.

Leuk Lymphoma. 2012 Feb;53(2):275-81. doi: 10.3109/10428194.2011.606943. Epub 2011 Sep 23.


Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.

Martinez-Lopez J, Blade J, Mateos MV, Grande C, Alegre A, García-Laraña J, Sureda A, de la Rubia J, Conde E, Martinez R, de Arriba F, Viguria MC, Besalduch J, Cabrera R, Gonzalez-San Miguel JD, Guzman-Zamudio JL, Gomez del Castillo MC, Moraleda JM, García-Ruiz JC, San Miguel J, Lahuerta JJ; Grupo Español de MM; Programa para el Estudio de la Terapé utica en Hemopatía Maligna.

Blood. 2011 Jul 21;118(3):529-34. doi: 10.1182/blood-2011-01-332320. Epub 2011 Apr 11.


Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.

Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, Goldschmidt H, Hajek R, Lee JH, Sezer O, Barlogie B, Crowley J, Fonseca R, Testoni N, Ross F, Rajkumar SV, Sonneveld P, Lahuerta J, Moreau P, Morgan G; International Myeloma Working Group.

Leukemia. 2013 Mar;27(3):711-7. doi: 10.1038/leu.2012.282. Epub 2012 Oct 3.


International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.

Waheed S, Shaughnessy JD, van Rhee F, Alsayed Y, Nair B, Anaissie E, Szymonifka J, Hoering A, Crowley J, Barlogie B.

Cancer. 2011 Mar 1;117(5):1001-9. doi: 10.1002/cncr.25535. Epub 2010 Oct 13. Erratum in: Cancer. 2011 Jul 1;117(13):3060.


Multiple myeloma in elderly patients: prognostic factors and outcome.

Anagnostopoulos A, Gika D, Symeonidis A, Zervas K, Pouli A, Repoussis P, Grigoraki V, Anagnostopoulos N, Economopoulos T, Maniatis A, Dimopoulos MA.

Eur J Haematol. 2005 Nov;75(5):370-5.


High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.

Dimopoulos MA, Barlogie B, Smith TL, Alexanian R.

Ann Intern Med. 1991 Dec 15;115(12):931-5.


[Clinical study of multiple myeloma: a report of 182 cases].

Xu L, Wang Y, Wu W, Yan H, Gao XD, Yu Q, Shen ZX, Mi JQ.

Zhonghua Yi Xue Za Zhi. 2010 Apr 13;90(14):972-7. Chinese.


[Treatment options and prognosis in newly diagnosed multiple myeloma patients].

Wang L, Tang W, Wang Y, Xu L, Zhao WL, Wu W, Chen YB, Shen ZX, Hu J.

Zhonghua Xue Ye Xue Za Zhi. 2011 May;32(5):308-12. Chinese.


Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.

Harousseau JL, Avet-Loiseau H, Attal M, Charbonnel C, Garban F, Hulin C, Michallet M, Facon T, Garderet L, Marit G, Ketterer N, Lamy T, Voillat L, Guilhot F, Doyen C, Mathiot C, Moreau P.

J Clin Oncol. 2009 Dec 1;27(34):5720-6. doi: 10.1200/JCO.2008.21.1060. Epub 2009 Oct 13.


Revised International Staging System Applied to Real World Multiple Myeloma Patients.

Jimenez-Zepeda VH, Duggan P, Neri P, Rashid-Kolvear F, Tay J, Bahlis NJ.

Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):511-518. doi: 10.1016/j.clml.2016.06.001. Epub 2016 Jun 8.


Supplemental Content

Support Center